Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a global medical technology company whose news flow reflects its activity across anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. Company announcements frequently highlight portfolio developments, clinical research, financial performance, and governance changes, giving investors and healthcare professionals insight into how the business is evolving.
Recent Teleflex news has included leadership transitions, with the Board appointing a long-serving director as Interim President and Chief Executive Officer and naming a new Chair of the Board, as well as updates on the search for a permanent CEO. The company has also reported on strategic portfolio actions, such as agreements to sell its Original Equipment Manufacturing and Development Services business and its acute care and interventional urology segments, reflecting a shift toward a more focused organization centered on core critical care and high-acuity hospital markets.
On the operational side, Teleflex regularly issues quarterly earnings releases and outlook updates, detailing revenue by region and global product category, along with commentary on non-GAAP measures like adjusted revenue and adjusted constant currency revenue growth. Dividend declarations and share repurchase authorizations are also communicated through press releases and associated SEC filings.
For those following clinical and product developments, Teleflex news covers topics such as the launch of the Barrigel™ rectal spacer in new markets and support for investigator-initiated trials like the DUBSTENT DIABETES study in interventional cardiology. Visitors to this TFX news page can review these updates in one place to understand how Teleflex’s strategy, portfolio, and financial profile are changing over time.
Teleflex (NYSE: TFX) will hold a conference call on October 27, 2022, at 8:00 a.m. ET to discuss its third-quarter financial results and operational updates. Participants can pre-register via the provided link or join via a live audio webcast on the company’s website. An audio replay will be accessible after 11:00 a.m. ET on the same day. Teleflex specializes in medical technologies that enhance health outcomes, with a diverse portfolio spanning vascular access, anesthesia, and surgical care.
Teleflex Incorporated has successfully acquired Standard Bariatrics, Inc. for $170 million, with potential additional payments of up to $130 million based on commercial milestones. This acquisition aims to enhance Teleflex's product offerings in bariatric surgery via advanced powered stapling technology. Notably, while the transaction is not expected to materially impact revenue for 2022 and is estimated to dilute adjusted earnings per share by approximately $0.10, it is projected to generate $30-$35 million in revenue for 2023, with further accretive effects on revenue and earnings thereafter.
Teleflex Incorporated (NYSE: TFX) has launched its new Arrow® Pressure Injectable Midline portfolio in the US and Canada as of September 27, 2022. This portfolio includes the Arrowg+ard Blue Advance® Midline designed to enhance patient safety by reducing confusion in line identification, which can lead to medication errors. With 14 kit configurations and features such as antimicrobial protection and eye-catching labeling, it aims to improve procedural efficiency. The innovation stems from collaboration with vascular access professionals.
Teleflex Incorporated (NYSE: TFX) announced the successful findings from the largest real-world evaluation of the MANTA® Device, presented by Dr. Magnus Settergren at the Transcatheter Cardiovascular Therapeutics (TCT) conference. The study, involving 1,048 subjects, showed a 4.2% major vascular complication rate, consistent with previous studies. The MANTA® Device, with over 100,000 units sold globally, is recognized for its safety, effectiveness, and short learning curve, enhancing its applicability in vascular closure for transcatheter aortic valve implantations.
Teleflex Incorporated (NYSE: TFX) will present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 10:00 a.m. ET. The speech will be delivered by Liam Kelly, the Chairman, President, and CEO of Teleflex. A live audio webcast of the presentation will be available on the investor section of the Teleflex website. Teleflex specializes in medical technologies that enhance health and quality of life, focusing on innovations in various fields such as vascular access and anesthesia.
Teleflex (NYSE: TFX) has partnered with FundamentalVR to launch a virtual reality (VR) training platform for its UroLift® 2 System, targeting the treatment of benign prostatic hyperplasia (BPH). The platform allows urologists globally, including in newly approved markets like Japan, to practice procedures remotely with tactile feedback and realistic simulations. The training solution aims to improve clinical education access and standardization. Teleflex's UroLift® System is recognized for its minimally invasive approach and lack of new onset erectile dysfunction, benefiting over 350,000 men worldwide.
Teleflex Incorporates Acquisition
Teleflex (NYSE: TFX) announced on August 22, 2022, a definitive agreement to acquire Standard Bariatrics for $170 million in cash, with potential additional payments of up to $130 million based on commercial milestones. The transaction, expected to close in Q4 2022, aims to enhance Teleflex's presence in the sleeve gastrectomy market. Standard Bariatrics anticipates 2022 revenues of $15 million, with expected contributions of $30-$35 million in 2023. However, the acquisition is projected to dilute adjusted earnings per share by $0.10 in 2022 and $0.10 to $0.15 in 2023.
Teleflex (NYSE: TFX) has secured a contract with Vizient, effective August 1, 2022, for supplying Central Venous Access products. This deal allows Vizient's members, which include over 50% of U.S. acute care providers, to access pre-negotiated pricing on Teleflex's products. Teleflex, a market leader in Central Venous Catheters, aims to enhance patient outcomes and minimize complications. The agreement includes Arrowg+ard Blue Plus® CVCs, which significantly reduce central line-associated infections, showcasing Teleflex's commitment to innovation in vascular access.
Teleflex Incorporated (NYSE: TFX) published its 2021 Global Impact Report, outlining achievements in its Corporate Social Responsibility (CSR) program. The report aligns with the Global Reporting Initiative and Sustainability Accounting Standards Board standards.
Key highlights include commitments to reduce energy, water use, and waste, along with the installation of solar panels generating over 5 GWh of renewable electricity. The report emphasizes diversity, equity, and inclusion efforts and investments in tracking environmental metrics, showcasing the company's dedication to ethical governance, sustainability, and community impact.
Teleflex Incorporated (NYSE: TFX) has declared a quarterly cash dividend of $0.34 per share, payable on September 15, 2022. Shareholders of record as of August 15, 2022 will receive this dividend. The company focuses on medical technologies aimed at enhancing health and quality of life, with a diverse product portfolio across various medical fields. For more information, visit teleflex.com.